人工T細胞市場：タイプ、用途、エンドユーザー別-2025-2030年の世界予測

人工T細胞市場は、2023年に27億3,000万米ドルと評価され、2024年には34億3,000万米ドルに達すると予測され、CAGR 25.72％で成長し、2030年には135億6,000万米ドルになると予測されています。

人工T細胞は、主に免疫療法で使用され、がん細胞をよりよく認識し攻撃するように患者のT細胞を改変します。この範囲には、キメラ抗原受容体（CAR）T細胞療法とT細胞受容体（TCR）療法が含まれます。人工T細胞の必要性は、従来の治療法と比較して副作用を低減した標的がん治療を提供できる可能性から生じる。様々な血液がんや一部の固形がんに応用されています。最終用途は病院、研究機関、バイオテクノロジー企業など多岐にわたる。市場成長は、遺伝子編集技術の進歩、世界のがん罹患率の増加、民間および政府による多額の投資が後押ししています。主なビジネスチャンスは、固形がんへの応用拡大、安全性プロファイルの改善、入手しやすくするための既製T細胞製品の開発にあります。しかし課題としては、高い治療費、複雑な製造工程、規制上のハードルなどがあります。また、重篤な副作用、再発の可能性、遺伝子改変に関する倫理的懸念といった市場の抑制要因もハードルとなっています。これらの課題に対処するためには、精密な遺伝子編集のためのCRISPR-Cas9の技術革新、より良い患者選択のための新規バイオマーカーの開発、自動化された製造工程が重要です。特に、腫瘍微小環境の理解を深め、がん細胞の耐性メカニズムに取り組む研究は有望です。製薬企業との共同研究、戦略的パートナーシップ、研究開発への投資は、事業成長のための戦略です。さらに、国際的な規制基準を調和させることで、承認と市場参入を合理化することができます。全体として、市場は急速な科学的進歩と規制状況の変化を特徴とするダイナミックな性質を示します。研究開発への戦略的投資と治療適応拡大への注力は、大きな配当をもたらす可能性があります。現在進行中の課題に適切に対処することができれば、有効性と安全性を向上させた治療薬を開発するチャンスは十分にあります。

市場力学：急速に進化する人工T細胞市場の主要市場インサイトを公開

人工T細胞市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • がん疾患の有病率の上昇
  • 革新的なバイオ医薬品治療に対する需要の増加
  • CAR-T細胞工学の最近の進歩
• 市場抑制要因
  • 人工T細胞治療に伴う高コスト
• 市場機会
  • 研究開発資金により活況を呈する免疫腫瘍学分野
  • 遺伝子治療市場の拡大
• 市場の課題
  • 人工T細胞の安全性の問題と副作用の可能性

ポーターの5つの力：人工T細胞市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、人工T細胞市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：人工T細胞市場における外部からの影響の把握

外部マクロ環境要因は、人工T細胞市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析人工T細胞市場における競合情勢の把握

人工T細胞市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス人工T細胞市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、人工T細胞市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨人工T細胞市場における成功への道筋を描く

人工T細胞市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • がん疾患の罹患率の上昇
    • 革新的なバイオ医薬品療法の需要増加
    • CAR-T細胞工学の最近の進歩
  • 抑制要因
    • 人工T細胞治療に関連する高コスト
  • 機会
    • 研究開発資金の投入により免疫腫瘍学分野が活況
    • 遺伝子治療市場の拡大
  • 課題
    • 人工T細胞の安全性の問題と副作用の可能性
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 人工T細胞市場：タイプ別

• キメラ抗原受容体
• T細胞受容体
• 腫瘍浸潤リンパ球

第7章 人工T細胞市場：用途別

• 乳がん
• 大腸がん
• 白血病
• 肺がん
• 悪性黒色腫

第8章 人工T細胞市場：エンドユーザー別

• がん研究センター
• クリニック
• 病院

第9章 南北アメリカの人工T細胞市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の人工T細胞市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの人工T細胞市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amgen Inc.
• Autolus
• Bellicum Pharmaceuticals, Inc.
• Bristol Myers Squibb
• Cabaletta Bio, Inc.
• ElevateBio, LLC
• Elli Lilly and Company
• Gilead
• Kuur Therapeutics by Athenex
• Novartis AG
• Oxford BioMedica
• Pfizer Inc.
• Precision Biosciences
• Tmunity Therapeutics Inc.
• TScan Therapeutics, Inc.

LIST OF FIGURES

• FIGURE 1. ENGINEERED T CELLS MARKET RESEARCH PROCESS
• FIGURE 2. ENGINEERED T CELLS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ENGINEERED T CELLS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ENGINEERED T CELLS MARKET DYNAMICS
• TABLE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY T CELL RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. CANADA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. MEXICO ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. CHINA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. INDIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. INDONESIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. JAPAN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. MALAYSIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. PHILIPPINES ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. SINGAPORE ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. TAIWAN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. THAILAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. VIETNAM ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. DENMARK ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. EGYPT ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. FINLAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. FRANCE ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. GERMANY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. ISRAEL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 105. ITALY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. NETHERLANDS ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. NIGERIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. NORWAY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. POLAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. QATAR ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SAUDI ARABIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH AFRICA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SPAIN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. SWEDEN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. SWITZERLAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. TURKEY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. UNITED ARAB EMIRATES ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 149. ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2023

The Engineered T Cells Market was valued at USD 2.73 billion in 2023, expected to reach USD 3.43 billion in 2024, and is projected to grow at a CAGR of 25.72%, to USD 13.56 billion by 2030.

Engineered T cells, primarily used in immunotherapy, involve modifying patients' T cells to better recognize and attack cancer cells. This scope includes Chimeric Antigen Receptor (CAR) T-cell therapy and T-cell Receptor (TCR) therapy. The necessity of engineered T cells arises from their potential to provide targeted cancer treatments with reduced side effects compared to traditional therapies. Applications extend to various hematologic cancers and some solid tumors. End-use scopes span hospitals, research institutes, and biotechnology companies. Market growth is propelled by advancements in gene-editing technologies, increasing incidences of cancer worldwide, and substantial private and governmental investments. Key opportunities lie in expanding applications in solid tumors, improving safety profiles, and developing off-the-shelf T cell products to enhance accessibility. However, challenges include high treatment costs, complex manufacturing processes, and regulatory hurdles. Market limitations such as severe side effects, potential relapse cases, and ethical concerns regarding genetic modifications also present hurdles. To combat these challenges, innovations in CRISPR-Cas9 for precise gene editing, developing novel biomarkers for better patient selection, and automated manufacturing processes are critical. Research is particularly promising in enhancing tumor microenvironment understanding and tackling cancer cell resistance mechanisms. Pharmaceutical collaborations, strategic partnerships, and investments in R&D are strategies for business growth. Additionally, harmonizing international regulatory standards can streamline approvals and market access. Overall, the market displays a dynamic nature, characterized by rapid scientific advancements and shifting regulatory landscapes. Strategic investments in R&D, coupled with a focus on expanding therapeutic indications, could yield significant dividends. Opportunities are ripe for exploitation in developing therapies with improved efficacy and safety profiles, provided that ongoing challenges are adeptly managed.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Engineered T Cells Market

The Engineered T Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in prevalence of cancer diseases
  • Increasing demand for innovative biopharmaceutical therapies
  • Recent advances in CAR-T cell engineering
• Market Restraints
  • High cost associated to engineered T cells treatment
• Market Opportunities
  • Immuno-oncology sector booming with R&D funding
  • Expanding gene therapy marketspace
• Market Challenges
  • Safety issues and possible side-effects with engineered T cells

Porter's Five Forces: A Strategic Tool for Navigating the Engineered T Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Engineered T Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Engineered T Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Engineered T Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Engineered T Cells Market

A detailed market share analysis in the Engineered T Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Engineered T Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Engineered T Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Engineered T Cells Market

A strategic analysis of the Engineered T Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Engineered T Cells Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Autolus, Bellicum Pharmaceuticals, Inc., Bristol Myers Squibb, Cabaletta Bio, Inc., ElevateBio, LLC, Elli Lilly and Company, Gilead, Kuur Therapeutics by Athenex, Novartis AG, Oxford BioMedica, Pfizer Inc., Precision Biosciences, Tmunity Therapeutics Inc., and TScan Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Engineered T Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Chimeric Antigen Receptor, T Cell Receptor, and Tumor-Infiltrating Lymphocytes.
• Based on Application, market is studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, and Melanoma.
• Based on End-User, market is studied across Cancer Research Centers, Clinics, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in prevalence of cancer diseases
    • 5.1.1.2. Increasing demand for innovative biopharmaceutical therapies
    • 5.1.1.3. Recent advances in CAR-T cell engineering
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated to engineered T cells treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Immuno-oncology sector booming with R&D funding
    • 5.1.3.2. Expanding gene therapy marketspace
  • 5.1.4. Challenges
    • 5.1.4.1. Safety issues and possible side-effects with engineered T cells
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Engineered T Cells Market, by Type

• 6.1. Introduction
• 6.2. Chimeric Antigen Receptor
• 6.3. T Cell Receptor
• 6.4. Tumor-Infiltrating Lymphocytes

7. Engineered T Cells Market, by Application

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Colorectal Cancer
• 7.4. Leukemia
• 7.5. Lung Cancer
• 7.6. Melanoma

8. Engineered T Cells Market, by End-User

• 8.1. Introduction
• 8.2. Cancer Research Centers
• 8.3. Clinics
• 8.4. Hospitals

9. Americas Engineered T Cells Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Engineered T Cells Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Engineered T Cells Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Autolus
• 3. Bellicum Pharmaceuticals, Inc.
• 4. Bristol Myers Squibb
• 5. Cabaletta Bio, Inc.
• 6. ElevateBio, LLC
• 7. Elli Lilly and Company
• 8. Gilead
• 9. Kuur Therapeutics by Athenex
• 10. Novartis AG
• 11. Oxford BioMedica
• 12. Pfizer Inc.
• 13. Precision Biosciences
• 14. Tmunity Therapeutics Inc.
• 15. TScan Therapeutics, Inc.